ASH 2018 | Dara-VRd for newly diagnosed myeloma: efficacy and safety data

Peter Voorhees

Peter Voorhees, MD, of Levine Cancer Institute, Charlotte, NC, discusses the safety and efficacy results for daratumumab, bortezomib, lenalidomide and dexamethasone (dara‐VRd) in ASCT-eligible newly diagnosed multiple myeloma patients from the Phase II GRIFFIN study (NCT02874742). Dr Voorhees reveals the encouraging tolerability, safety and response data from this trial.

Share this video